|
Multiple Myeloma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We identified the Bcl2 family member MCL1 and several 26S proteasome subunits among the most important and selective multiple myeloma survival genes.
|
22147262 |
2012 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Small interfering RNA of cyclooxygenase-2 induces growth inhibition and apoptosis independently of Bcl-2 in human myeloma RPMI8226 cells.
|
17588340 |
2007 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, our data suggest that the protective effects of bcl-2 in MM cells act upstream in the NF-kappaB activation-signaling pathway and the potential use of NF-kappaB as a biomarker in progressive MM.
|
10216101 |
1999 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, our data demonstrates that loss of p53 function leads to myeloma cell progression and resistant phenotype through bcl-2-related mechanisms.
|
12479855 |
2003 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that if BCL2 deregulation does indeed occur in MM, a mechanism other than translocation must be involved in most cases.
|
1415486 |
1992 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Myeloid cell leukemia-1 (Mcl-1, HGNC: 6943), a pro-survival member of the Bcl-2 family, plays a crucial role in Multiple Myeloma (MM) pathogenesis and drug resistance, thus representing a promising therapeutic target in MM.
|
24120758 |
2014 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Altogether, the identification of a subset of cell lines and primary cells effectively killed by ABT-737 alone supported the evaluation of ABT-263, an orally active counterpart to ABT-737, for the treatment of t(11;14) and hyperdiploid groups of myeloma harboring a Bcl-2(high)/Mcl-1(low) profile.
|
21835956 |
2011 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, we provide first time evidence that similar to Fas, TRAIL-induced apoptosis is not blocked by bcl-2 in MM cell lines.
|
10557057 |
1999 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ongoing clinical trials are exploring the role of Bcl-2 downregulation with oblimersen (Bcl-2 antisense) in patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia and multiple myeloma.
|
15784299 |
2005 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As wogonin was effective in vitro in promotion of apoptosis of myeloma cell by Akt-modulated, Bax and Bcl-2 related intrinsic apoptotic pathway, wogonin may be a potential therapeutic agent against multiple myeloma.
|
23142241 |
2013 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We studied eight myeloma cell lines for the presence of Bcl-2, which inhibits apoptosis, of Bax, which counteracts Bcl-2, of Bcl-x(L) and Bcl-x(S), which act in an anti- and pro-apoptotic fashion, respectively, and of Apo-1/Fas, which induces programmed cell death, when activated by the Apo-1/Fas ligand or the relevant monoclonal antibody (mab).
|
9163609 |
1997 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bcl-2 mediated suppression of apoptosis in myeloma NS0 cultures.
|
10812183 |
2000 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo.
|
23708869 |
2013 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bcl-2 inhibitors and HDAC inhibitors were proved their anti-MM effect in clinic or under clinical trials, and they were further discovered to have synergistic interactions.
|
30594434 |
2019 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1.
|
11175262 |
2000 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Myeloid cell leukemia-1 (Mcl-1) protein is an anti-apoptotic Bcl-2 family protein that plays essential roles in multiple myeloma (MM) survival and drug resistance.
|
22128141 |
2012 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review will focus on Bcl-2 and the mevalonate pathway as targets for reversal of drug resistance in multiple myeloma.
|
16454747 |
2006 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Translocation t(11;14) has emerged as the first predictive marker in MM, indicating susceptibility to BCL2 inhibition.
|
31818702 |
2019 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since both IL-6 and bcl-2 protein have been shown to prevent programmed cell death, this may be the unifying event in MM.
|
8467229 |
1993 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the association between the expression of anti-apoptotic members of the Bcl-2 family and the efficacy of bortezomib in patients with relapsed/refractory MM.
|
22054286 |
2012 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
CTD_human |
MM cells express multiple Bcl-2 family members, including Bcl-2, Bcl-XL, and Mcl-1, which are thought to play a key role in the survival and drug resistance of myeloma.
|
12429644 |
2002 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study we demonstrate that direct inhibition of anti-apoptotic BCL2 proteins with ABT-263 is sufficient to induce C(16)-ceramide synthesis in multiple cell lines, including human leukaemia and myeloma cells.
|
23480852 |
2013 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Venetoclax is a selective, orally bioavailable BCL-2 inhibitor that induces cell death in multiple myeloma (MM) cells, particularly in those harboring t(11;14), which express high levels of BCL-2 relative to BCL-X<sub>L</sub> and MCL-1.
|
29018077 |
2017 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review addresses the role and regulation of pro-survival BCL-2 family proteins during healthy PC differentiation and in MM, as well as their potential as therapeutic targets.
|
30524962 |
2018 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Accelerated plasmacytomagenesis in strain C.BCL2 may be useful for designing and testing BCL2 inhibition strategies in human plasma cell tumors overexpressing BCL2, such as Waldenström's macroglobulinemia and multiple myeloma.
|
14695177 |
2003 |